Novartis strikes about $7.8 billion mRNA deal with China's Abogen
02/10/2026 08:29
Novartis strikes about $7.8 billion mRNA deal with China's Abogen Oct 2 (Reuters) - Chinese biotech company Abogen said on Friday it signed a licensing and option agreement worth about $7.8 billion with Swiss drug maker Novartis NOVN.S to advance RNA-based therapy.
(Reporting by Ruchika Khanna in Bengaluru; Editing by Subhranshu Sahu)
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant